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Abstract
Cytotoxic T lymphocytes (CTLs) are primed by peptide antigens that are endogenously processed in the cytosol and presented in the
context of major histocompatibility complex I (MHC I) molecules of antigen-presenting cells (APCs). Exogenous soluble protein antigens do
not gain efficient entry into the cytosol of APCs, and therefore requires a special cytosolic delivery method. We have developed such a
delivery strategy adopting the well-elucidated cytosol-invading listerial endosomal escape mechanism, and report here an efficient delivery of
exogenous whole protein antigen into the cytosol in a mouse model. Co-encapsulation of listeriolysin O (LLO) inside liposome (LLO-
liposome) was required for delivery of ovalbumin (OVA) into the cytosol of APCs in primary cultures. LLO-liposome-mediated OVA
immunization in mice engendered significantly higher OVA-specific CTL activity and increased antigenic peptide-specific CTL precursor
(CTLp) frequency as compared to non-LLO-liposome or soluble OVA immunizations. Interferon-g (IFN-g) production upon specific
stimulation by MHC I-restricted peptide was also significantly stronger by the inclusion of LLO in the liposomes. Rerouting of antigen into
the cytosol by LLO-liposomes, however, did not reduce the extent of anti-OVA antibody responses. Moreover, LLO-liposome-antigen
vaccination was robust in conferring protection to mice from lethal challenges with antigen-expressing tumor cells. Our study demonstrates a
novel delivery system for efficient introduction of exogenous protein into the cytosol in vivo, priming cellular immune responses, which are
protective in nature. D 2002 Elsevier Science B.V. All rights reserved.
Keywords: Liposomal antigen delivery; In vivo animal model; MHC I; CTL vaccine; Endosomolysis; CTLp; ELISPOT; IFN-g response; Tumor protection
1. Introduction
Development of delivery strategies for efficient introduc-
tion of macromolecular therapeutic agents into the cytosolic
compartment of cells is a critical issue [1]. Specifically, as
one of the important in vivo applications of cytosolic
delivery, an efficient introduction of exogenous whole pro-
tein antigen is required for induction of an enhanced antigen-
specific cytotoxic T lymphocyte activity, which is a key
immune response in anti-tumor and anti-viral immune ther-
apy [2]. The cytotoxic T lymphocytes (CTLs) are primed by
antigen-derived peptides that are generated in the cytosol via
the proteasome-mediated pathway and subsequently pre-
sented in the context of major histocompatibility complex I
(MHC I) molecules of antigen-presenting cells (APCs) to
CD8 + T cells [3]. Exogenous soluble protein antigens used
for vaccines, however, typically do not gain efficient entry
into the cytosolic compartment of cells. Therefore, develop-
ment of a method that primes CTLs depends critically on a
special cytosolic delivery strategy designed to circumvent
endosomal degradation and overcome the membrane barrier.
Several studies have provided various methods and
mechanisms leading to the delivery of exogenous proteins
for MHC I-mediated presentation [4–9]. With some varia-
tions, other strategies also include live attenuated intracel-
lular bacterial strains carrying CD8 + T cell epitopes or
proteins into the cytosol [10,11]. These existing approaches,
however, often pose unique and inherent concerns regarding
their efficacy in vivo, safety, limited ability to carry multiple
copies of antigenic macromolecules, or impracticality for
pharmaceutical formulation, thus limiting their clinical appli-
cations [12].
We have rendered liposomes capable of efficient cytosolic
delivery by adopting the mechanism from a unique endo-
some-escaping, cytosol-invading bacterium, Listeria mono-
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cytogenes [13,14]. Liposomes, as potential universal carriers
of therapeutic agents, offer several advantages with proven
human applications for vaccination [15], but possess limited
capability for efficient introduction of macromolecules into
the cytosol. This is primarily because most liposomal for-
mulations, unless cationic or pH-sensitive, are taken up into
the endosomal compartment of APCs and by default deliver
antigens predominantly into the MHC II compartments. The
in vitro study by Lee et al. [16] significantly improved the
efficiency of liposome-mediated cytosolic delivery by co-
encapsulating purified listeriolysin O (LLO) inside lipo-
somes and pH-sensitive liposomes. LLO is the major viru-
lence factor and causative component for phagosomal escape
of the facultative intracellular bacteria Listeria into the
cytosol of host cells [13]. LLO-mediated endosomal escape
of exogenous immunogens into the cytosolic space has also
been documented using Listerial vector [17–20] or engi-
neered E. coli [21]. Despite their success in exploiting the
efficient membrane pore-forming capability of LLO, the
existing LLO-based approaches, other than LLO-liposomes,
may not be well suited for a universal delivery strategy
because of their safety and toxicity issues, particularly with a
goal toward human applications and vaccination [22]. There-
fore, extending our previous in vitro observations that
elucidated the concept and mechanism of LLO-liposome
[16], we report here efficient in vivo cytosolic delivery of a
model antigen, ovalbumin (OVA), using LLO-containing,
pH-sensitive liposomes with a major focus on the MHC I-
mediated induction of naı¨ve CTL precursors for enhanced
CTL response. Numerous parameters, such as augmented
MHC I-restricted antigen presentation and cytokines, influ-
ence the magnitude and character of a primary CD8 + T cell
response [23]. To investigate further the role of cytosolic
delivery in generating CTL response specific for exogenous
antigen, we have monitored the frequency of antigen-spe-
cific cytotoxic T lymphocyte precursor (CTLp) by a sensi-
tive enzyme-linked immunospot (ELISPOT) assay, and also
examined several functional correlates of the immune
responses such as cytokine secretion, antigenic memory,
and anti-tumor ability of the CTL in vivo. The results
presented here show that LLO-liposome-mediated OVA
immunization generates stronger OVA-specific CTL activity,
higher MHC class I OVA-peptide-specific CTLp frequency
as well as primes stronger and longer-lasting interferon g
(IFN-g) response. Importantly, we further show that the
MHC I-dependent CTL response engendered by the efficient
cytosolic delivery is functionally robust in protecting mice
against lethal challenge of a tumor cell line expressing the
specific antigen. Even though some of the antigens are
routed into the cytosol away from the MHC II compartment,
the antigen-specific antibody response was not diminished,
implying that this delivery system can provide an extremely
powerful modality of generating both cellular and humoral
immune responses using whole protein antigen.
Our data provide convincing evidence for the applicabili-
ty of this delivery vehicle in an animal model system, thus
proving its general usefulness and suggesting potential of
this broadly enabling strategy in clinical settings.
2. Materials and methods
2.1. Purification of LLO and preparation of liposomes
containing LLO/OVA
Recombinant LLO (rLLO) was purified from E. coli
strain BL21 (DE3) transformed with pET29b plasmid
(Novagen, WI) carrying six histidine (His6)-tagged LLO
gene (from D. Portnoy, University of California, Berkeley)
using Ni-NTA affinity resin (Qiagen, CA). The His6-tagged
LLO cDNA (1.6 kb) lacking the secretion signal was made
by PCR incorporation of nucleotides encoding His6-resi-
dues within the 3V PCR primer immediately before the LLO
stop codon [21]. Bacterial culture was induced 4 h for LLO
overexpression by isopropyl h-D-thiogalactopyranoside, and
afterwards cell pellet was lysed by sonication. Lysate super-
natant was adsorbed to Ni-NTA agarose and the matrix was
washed extensively with PBS containing 20 mM imidazole,
1 mM PMSF, pH 8.0. His6-tagged rLLO was eluted with
PBS containing 500 mM imidazole and dialyzed with 10
mM HEPES containing 140 mM NaCl, 1 mM EDTA, pH
8.3 at 4 jC. Protein purity was analyzed by SDS-PAGE,
concentration by BCA protein assay (Pierce, IL). rLLO was
immuno-detected by an anti-LLO rabbit serum (obtained
from Dr. Portnoy; originally generated in the laboratory of P.
Cossart, Pasteur Institute, France [24]), in Western blot, and
its membrane pore-forming activity was monitored by
hemolysis assay [16]. pH-sensitive liposomes [phosphati-
dylethanolamine (PE)/cholesteryl hemisuccinate (CHEMS),
2:1 molar ratio (Avanti Polar Lipids, AL, Sigma, MO)]
containing OVA (grade VI, Sigma, 20 mg/ml) with or
without LLO were prepared, un-encapsulated proteins
removed by gel filtration using Sepharose CL-4B (Amer-
sham Pharmacia Biotech, Sweden) as described previously
[16], and the encapsulated OVA and LLO concentrations
were determined by quantitative SDS-PAGE and densitom-
etry. The size of the liposomes was measured by quasi-
elastic light scattering (Nicomp, PA).
2.2. Animals, cell lines, peptides
C57BL/6J (B6) mice (H-2b, 4–6-week-old female; Jack-
son Lab., ME) were handled according to the Institutional
Guideline. The target cells EL-4 (H-2b, a B6-derived thy-
moma) and E.G7-OVA (E.OVA, a subclone of EL-4 stably
transfected with pAc-neo-OVA gene) [4] were purchased
from the American Type Culture Collection (VA). Cells
were grown in complete RPMI 1640 medium containing
10% heat-inactivated fetal bovine serum, 100 U/ml penicil-
lin, 100 Ag/ml streptomycin, 50 AM 2-ME (Life Technolo-
gies Inc., NY) with 400 Ag/ml geneticin for E.OVA. OVA
peptide SIINFEKL-specific CD8 + T cell hybridoma (CD8
M. Mandal, K.-D. Lee / Biochimica et Biophysica Acta 1563 (2002) 7–178
OVA T1.3, H-2Kb restricted, from Dr. C. Harding (Case
Western Reserve University, Cleveland)) was maintained in
complete DMEM. Murine CD8-specific monoclonal anti-
body (anti Lyt-2, 3.155) was obtained from Dr. J. Bluestone
(University of California, San Francisco). B16, a B6-derived
murine melanoma and MO5 (B16 transfected with pAc-neo-
OVA gene) were obtained from Dr. K.L. Rock [25] (Uni-
versity of Massachusetts, Worcester). Cells were grown in
complete RPMI 1640 medium containing 10% heat-inacti-
vated fetal bovine serum, 100 U/ml penicillin, 100 Ag/ml
streptomycin, 50 AM 2-ME (Life Technologies) with 2 mg/
ml geneticin plus 60 Ag/ml hygromycin B for MO5.
OVA peptide SIINFEKL (amino acids 257–264) and
vesicular stomatitis virus nucleoprotein peptide RGY-
VYQGL (amino acids 325 – 332) were synthesized
(Research Genetics, AL), dissolved in PBS and kept at
 80 jC in aliquots.
2.3. In vitro antigen presentation assay
Mouse bone marrow precursor-derived macrophages
were cultured in complete DMEM containing macrophage
colony-stimulating factor [16], and dendritic cells (DCs) in
complete RPMI containing granulocyte-macrophage col-
ony-stimulating factor and interleukin-4, and were enriched
on day 6 using a serum column [26]. In vitro antigen
delivery experiments in APCs were performed as described
[16]. Briefly, APCs were plated (2 105/well in 96-well
plates) in complete DMEM and were pulsed with liposomal
OVA/LLO or OVA alone in serum-free medium for 1 h at 37
jC. Cells were washed, incubated in complete medium for 4
h at 37 jC, and then fixed with 1% paraformaldehyde.
1105 OVA-specific CD8 + T cells, CD8 OVA T1.3, were
added to each well in 0.2 ml complete DMEM and further
incubated for 24 h at 37 jC in 5% CO2. Interleukin-2 (IL-2)
concentration in the culture supernatant was measured by
enzyme linked immunosorbent assay (ELISA) using Duoset
IL-2 assay kit (Genzyme Corporation, MA) to monitor
antigen presentation.
2.4. 51Cr release assay for OVA-specific CTL activity
Mice (4–6 mice/group) were immunized via subcuta-
neous (s.c.) or intravenous (i.v.) route on day 0 and day 12
with OVA in various formulations. Amount of injected OVA
ranged 35–50 Ag over three independent sets of experi-
ments, and was kept constant in the experimental and
control groups in each set. Splenocytes (responders) were
isolated 9–12 days after boost, and were restimulated in
vitro for 5 days with mitomycin-C (50 Ag/ml, 4 107 cells
for 25 min at 37 jC)-treated E.OVA cells (stimulators), as
described [4] without exogenous IL-2. Viable T cells sepa-
rated on a Ficoll gradient were used as effector cells in a
standard 4-h CTL assay [4] with 51Cr (Amersham Pharma-
cia Biotech, IL) labeled E.OVA, EL-4, or EL-4 pulsed with
SIINFEKL (10 Ag/ml) during 51Cr labeling for 1.5 h at 37
jC, as target cells. Released 51Cr from target cells was
measured in a gamma counter and specific cytolytic activity
was determined using the formula:
% specific lysis
¼ experimental release spontaneous release
total release spontaneous release  100
The spontaneous release was routinely between 5% and
15% of the total release of 51Cr from the target cells by
detergent lysis.
2.5. ELISPOT assay
Antigen-specific IFN-g-secreting effector T cells were
quantified by an ELISPOT assay [27] using the paired anti-
IFN-g antibodies R4-6A2 for capture and biotinylated
XMG1.2 for detection (PharMingen, CA). MAHA-S45
plate (Millipore, MA) was coated with the anti-IFN-g
capture antibody in sterile PBS overnight at 4 jC, and
blocked with 2% bovine serum albumin in PBS at room
temperature. Splenocytes from immunized mice were
depleted of red blood cells with Gey’s hemolytic solution
and cultured with SIINFEKL or RGYVYQGL (10 Ag/ml)
for 24 h at 37 jC in the plate. Spots were detected by adding
alkaline-phosphatase-conjugated streptavidin (PharMingen)
and visualized by adding 5-bromo-4-chloro-3-indolyl phos-
phate/nitroblue tetrazolium (BCIP/NBT) substrate. The fre-
quencies of IFN-g-producing cells in each well were
determined using a computerized ImmunoSpot Image Ana-
lyzer (Cellular Technology, OH).
2.6. Antigen-specific IFN-g production
Antigen-specific cytokine response was determined by
culturing the splenocytes (1107/ml) from the immunized
mice in the presence of OVA peptide SIINFEKL (10 Ag/ml),
nonspecific peptide RGYVYQGL (10 Ag/ml), or Con A (5
Ag/ml) in 96-well plates for 24 or 48 h [28]. IFN-g
concentration in the culture supernatant was measured by
enzyme-linked immunosorbent assay (ELISA) performed in
triplicate using the paired monoclonal antibodies (PharMin-
gen). IFN-g concentration was calculated based on the
recombinant mouse IFN-g (Genzyme Corporation, CA)
standards and expressed as IFN-g units/ml. For assessment
of antigenic recall memory, IFN-g secretion was measured
upon specific peptide stimulation to the splenocytes har-
vested from immunized mice 14.5 weeks post-boost.
2.7. OVA-specific antibody titer
OVA-specific IgG titer in immunized mice serum was
measured by ELISA using OVA (10 Ag/ml)-coated plates
(Immulon-II, Nunc, Denmark). Dilutions (1:1000, 1:10000,
1:20000) of the serum samples (pre-immune, pre-boost, and
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post-boost) obtained at different time points were added,
and OVA-specific antibody was detected with goat anti-
mouse IgG (FabV)2-biotin (Sigma Immunochemicals, MO).
The absorbance (O.D.) was read at 405 nm after developing
alkaline phosphatase-streptavidin with p-nitrophenyl phos-
phate (Sigma, MO).
2.8. In vivo tumor protection assay
Antigen-specific tumor protection assay was performed
as described [25] with modifications. Mice were immu-
nized s.c. twice at 12-day interval and challenged on day 7
post-boost via intradermal (i.d.) injection bilaterally with
2 105 melanoma cells, B16 or MO5 in 100 Al Hanks’
balanced salt solution. Tumor growth was monitored every
2–3 days by measuring two largest perpendicular diame-
ters, and the product was recorded as tumor size/area. Mice
that became moribund were euthanized following the
guidelines, and survival was scored as the percentage of
surviving animals.
2.9. Statistical analysis
Wilcoxon rank-sum (Mann–Whitney) test was applied to
determine the statistical significance (P-value) of the in vivo
experimental results among various groups. The Kruskal–
Wallist test was used to assess the P-value between lipo-
some formulations containing different concentrations of
LLO in the in vitro antigen presentation assay.
3. Results
3.1. Protein delivery into APCs in vitro
The LLO-liposome delivery vehicle was characterized
and optimized, before testing in mice, using the in vitro
antigen presentation assay in primary cultures of murine
macrophages and DCs. Affinity-purified, histidine-tagged
recombinant LLO migrated at f 58 kDa as a major band
in SDS-PAGE (Fig. 1 panel A) and used for encapsulation in
liposomes. The purification was confirmed by Western blot
using a polyclonal anti-LLO serum (panel B) and tested for its
functional activity by hemolysis assay (data not shown).
Hemolytic activity of purified rLLO per microgram of
protein, stored in aliquots at  20 jC, was retained at similar
levels over a period of months and its variability among
different batches was minimal (data not shown). Liposome-
encapsulated OVA or OVA/LLO was separated from non-
encapsulated species by gel filtration chromatography (panel
C). On average, the encapsulation efficiency was between 7%
and 15% and the mean diameter of the liposomes was in the
range of f 240–370 nm (SDF 118–180) as determined by
particle size analysis.
The extent of cytosolic delivery of the model antigenic
protein OVAby LLO-liposomes was dose-dependent of OVA
and concentration-dependent of LLO encapsulated inside
Fig. 1. Purification of rLLO and liposome-encapsulated proteins. (A) SDS-
PAGE of Ni-NTA affinity-purified rLLO; (B) immunoblot of purified
rLLO; and (C) liposome-encapsulated OVA or OVA/LLO separated by gel
filtration chromatography. Lanes: 1, molecular weight markers; 2, bacterial
lysate pellet; 3, bacterial lysate supernatant; 4, purified rLLO; 5,
immunoblot of rLLO; 6, liposome-encapsulated OVA; 7, liposome-
encapsulated OVA/LLO. Upper and lower arrows indicate the position of
LLO and OVA, respectively.
Fig. 2. rLLO-dependent cytosolic delivery of OVA in vitro in APCs.
Macrophages were pulsed with liposome-encapsulated OVA containing
varying concentrations of LLO (100–400 Ag/ml), washed, and incubated
for 4 h at 37 jC. Cells were then fixed by 1% paraformaldehyde, and co-
cultured with OVA-specific CD8 + T cells for 24 h. The extent of cytosolic
OVA-derived peptide presented to the T cells was measured in triplicate by
IL-2 ELISA. P-value is shown at 10 Ag/ml OVA concentration.
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liposomes (Fig. 2). With increasing LLO concentrations
encapsulated inside OVA-containing, pH-sensitive lipo-
somes, higher levels of MHC class-I (H-2Kb)-binding
OVA-peptide, SIINFEKL, were presented by the APCs to
CD8 + OVA-specific T cells, as detected by higher levels of
IL-2 secreted by the T cells, with an optimum range (200–
400 Ag/ml) of LLO concentration for efficient cytosolic
delivery (Fig. 2). No IL-2 was detected when cells were
incubated either with non-liposomal soluble OVA or with
OVA encapsulated in non-LLO-liposomes, demonstrating
that co-encapsulation of LLO is required for introduction of
exogenous OVA into the cytosol of APCs. When macro-
Fig. 3. Strong OVA-specific cytolytic activity generated by LLO-liposome-OVA immunization. (A) Mice were immunized s.c. with liposome-encapsulated
OVA, with or without LLO, or free soluble OVA, and monitored for OVA-specific CTL by the standard 51Cr release assay. Each data point represents the mean
cytolytic activity of triplicate cultures of the splenocytes pooled from two immunized mice in each group (n= 4). The representative data are from one set of
immunization, and experiments were repeated three times with similar results. (B) Analysis of OVA-specific CTL assay results from three independent sets of
s.c. immunization experiments at 11:1 effector/target ratio (n= 12 per group).
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phages derived from BALB/c mice (H-2Kd background)
were used in this assay, no OVA presentation was observed
(data not shown). Similar LLO-dependent delivery results
were observed with DCs; when OVA-pH-sensitive lipo-
somes were tested with and without co-encapsulated LLO at
250 Ag/ml concentration, efficient cytosolic delivery was
demonstrated in both macrophages and DCs in an LLO-
dependent manner albeit with different overall efficiencies
(data not shown).
3.2. Enhanced induction of OVA-specific CTL response by
LLO-liposome-mediated OVA delivery in vivo
The above in vitro experiments in APCs suggested a
hypothesis that the LLO-liposomal delivery system would
efficiently introduce exogenous proteins into the cytosolic
pathway of antigen presentation in vivo. This was tested by
monitoring the induction of antigen-specific CTL responses
in mice using OVA-pH-sensitive liposomes with and with-
out LLO. CTL assay results (Fig. 3A) show that s.c.
immunizations with OVA in the pH-sensitive, non-LLO-
liposomes generated relatively low but detectable levels of
OVA-specific CTL over the controls, free soluble OVA
immunization or placebo, as has been shown previously [8].
The OVA-specific CTL activity, however, was significantly
enhanced using LLO-liposomes over non-LLO-liposomes.
The cytolytic activity was MHC I (H-2Kb)-restricted OVA
peptide (SIINFEKL)-specific. This significant augmenta-
tion upon LLO co-encapsulation (P= 0.01), as examined
in three independent sets of experiments (summarized in
Fig. 3B), was in concordance with our hypothesis and the
in vitro results. Similar results were obtained with i.v.
immunizations (data not shown) demonstrating that LLO-
liposome-mediated cytosolic delivery is not restricted to
any particular route of administration. Treatment of the
effector cells with anti-murine CD8 monoclonal antibody
(mAb) during the 4-h incubation period of CTL assay
effectively inhibited their cytolytic activity; 87.6 % inhib-
ition was observed at 100:1 effector/target ratio.
3.3. Increased antigen-specific T cell frequency and en-
hanced antigen-specific cytokine production by LLO-lipo-
some-OVA immunization
We determined the antigen-specific CTLp, after immu-
nization with soluble OVA or liposomal OVA with or
without LLO co-encapsulation, using antigen-specific
IFN-g ELISPOT assays. This is to test if the observed
higher CTL activation by LLO-liposomal OVA immuniza-
tion, as monitored by the standard 51Cr release assay, is
indeed due to an increase in OVA-specific CTLp frequency.
Freshly isolated splenocytes from the immunized mice was
stimulated with the immuno-dominant, MHC class I H-2Kb
restricted OVA peptide SIINFEKL [4] and analyzed for
IFN-g-secreting cells. A significantly higher frequency of
SIINFEKL-specific IFN-g spots was observed (P < 0.05) in
the splenocytes isolated from the mice immunized with
LLO-liposome-OVA as compared to that with non-LLO-
liposome-OVA immunization (Fig. 4A).
Fig. 4. Higher CTLp frequency (A) and enhanced IFN-g production (B)
generated by LLO-liposome-OVA immunization. (A) Mice were immu-
nized s.c. with liposome-encapsulated OVA, with or without LLO, or free
soluble OVA twice at 12-day interval, and monitored for OVA-specific
CTLp frequency determined by ELISPOT assay between days 9 and 12
post-boost. Result is shown as IFN-g-specific spots per 106 or 0.3 106
cells/well (meanF S.E.); four mice per group in each experiment, and ex-
periment was repeated twice with similar results. (B) Enhanced production
of IFN-g by the spleen cells from the mice immunized with LLO-liposome-
OVA ( *P < 0.05). Mice were immunized i.v. with LLO-liposome-OVA or
non-LLO-liposome-OVA twice at 12-day interval. Spleen cells were har-
vested from the immunized mice, and stimulated in vitro either with OVA
peptide (SIINFEKL) or a control peptide (RGYVYQGL), at 10 Ag/ml. IFN-
g in the culture supernatant after 48-h culture was measured by ELISA.
Some of the wells were also treated with Con A (5 Ag/ml) as a positive
control (data not shown).
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IFN-g production by the splenocytes harvested from the
immunized mice, upon stimulation by the SIINFEKL, was
monitored as an additional measure of the cellular immunity
generated by LLO-liposome-mediated OVA immunization.
Splenocytes from the mice immunized with LLO-liposome-
OVA secreted significantly higher (P < 0.05) levels of IFN-g
(mean 101.9 SDF 32.4 units/ml) than those from the non-
LLO-liposome-OVA immunized group (mean 34.3 SDF 6.8
Fig. 5. OVA-specific IgG response. (A) Mice were immunized as described in Fig. 3, and OVA-specific IgG titer in the serum samples of the immunized mice
was determined by ELISA. (B) Long-term OVA-specific IgG response post-boost was monitored by ELISA over a 4-month period. Data shown as mean O.D.
(F SD) of the serum samples obtained at the indicated time points (n= 8 per group, A; n= 4 per group, B).
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units/ml) (Fig. 4B). Addition of a control peptide, RGY-
VYQGL, to the splenocytes stimulated very low levels of
cytokine produced in both groups, which were similar to the
basal level of IFN-g generated by splenocytes without
addition of peptide. Spleen cells from both groups exhibited
strong cytokine response when treated with the T cell mito-
gen, Con A (data not shown). Long-term antigen-specific
memory was assessed by monitoring IFN-g response of the
splenocytes harvested at 14.5 weeks post-immunization and
stimulated by the specific peptide SIINFEKL ex vivo. A
dramatic difference was also observed in the IFN-g produc-
tion between LLO-liposome-OVA and non-LLO-liposome-
OVA immunized groups, demonstrating the prolonged and
superior antigen-specific immunologic memory induced by
the LLO-liposomal formulation over the non-LLO-liposomal
formulation (data not shown).
3.4. OVA-specific antibody elicited by LLO-liposome-OVA
immunization
OVA-specific antibody titer was monitored from the
immunized mouse serum samples, concurrently with the
CTL assays, to investigate the effect of routing a significant
fraction of the internalized antigen from endocytic compart-
ments into the cytosolic pathway of antigen presentation.
Liposomal OVA immunizations induced comparably strong
Fig. 6. OVA-specific anti-tumor protective immunity. (A) Mice were immunized as in Fig. 3, and were challenged 7 days later (day 0) with 2 105 B16 or
MO5 melanoma cells. Data shown as average tumor area (F S.D.) are from one representative experiment of three independent sets. Each set of experiments
included 5–10 mice/group. (B) Prophylactic vaccination with LLO-liposome-OVA increases overall survival in response to tumor challenge.
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levels of OVA-specific antibody responses regardless of
LLO co-encapsulation inside the liposomes (Fig. 5A), in
comparison to minimally detectable antibody levels with the
non-liposomal, soluble OVA. Fig. 5B shows the long-term
anti-OVA IgG response monitored over a period of 120 days
post-immunization. Anti-OVA antibody response remained
robust during this period for both groups immunized with
liposomal OVA.
3.5. LLO-liposomal OVA immunization engenders protec-
tive immunity
The ability of LLO-liposome-induced antigen-specific
CTL in conferring protective immunity was evaluated in a
murine melanoma model. Mice were immunized s.c. with
LLO-liposome-OVA and challenged i.d. at multiple lethal
doses, approximately 20 times higher, with MO5 melanoma
cells, a stable clone of OVA-expressing B16, or with the
parental B16 melanoma cells. LLO-liposome-OVA immu-
nization elicited strong OVA-dependent anti-tumor immun-
ity as the immunized mice were protected from MO5
challenge, but not from the parental B16 challenge (Fig.
6A). A significant percentage of LLO-liposome-OVA
immunized mice survived and remained tumor-free with
MO5 challenge but not with B16 (Fig. 6B), in comparison
to placebo immunized control mice, which were equally
susceptible to B16 and MO5 challenge. The control groups
of mice rapidly developed tumors (by day 12) and most of
them died by day 18–20. Furthermore, approximately
f 30–40% of the LLO-liposome-OVA immunized mice
remained tumor-free and survived until day 150, when the
experiment was terminated (data not shown).
4. Discussion
Development of a vaccine delivery strategy for function-
ally robust CTL responses relies critically on the ability to
introduce exogenous antigenic proteins efficiently into the
cytosolic compartment of APCs. Our data on antigen-
specific CTL responses in mice demonstrate that the unique
utilization and formulation of LLO inside antigen-carrying,
pH-sensitive liposomes achieves this objective. This new
method of cytosolic delivery and consequent CTL induction
involves uptake of liposomal exogenous antigen into the
endocytic compartment of APCs and subsequent LLO-
mediated release of the endosomal contents into the cytosol
for classical cytosolic/MHC I pathways of antigen process-
ing and presentation, as previously documented in vitro
using a proteasome inhibitor and brefeldin A [16].
Expression of histidine-tagged LLO in E. coli and its
one-step affinity column purification allowed us to purify
the protein in large quantities. The purified recombinant
LLO was characterized by SDS-PAGE, Western blot (Fig.
1), and hemolysis assay for its functional activity, which has
been also confirmed by Gedde et al. [29]. As E. coli-based
expression system was used for rLLO used in this study, it
was difficult to eliminate the minute amounts of LPS in the
rLLO preparations and the liposomes. However, the con-
taminating level of LPS in the liposomes, with or without
encapsulated rLLO in comparison with no treatment, was
observed to have no detectable effect on macrophage
activation as monitored by cytokine mRNA induction
(Lee and Portnoy, unpublished data). As pH-sensitive PE/
CHEMS liposomes containing recombinant LLO was char-
acterized and optimized using the in vitro OVA presentation
assay in both macrophages and DCs, the extent of cytosolic
delivery of OVA by LLO-liposomes was concentration-
dependent of LLO encapsulated inside liposomes (Fig. 2).
It should be noted, consistent to the previous finding by Lee
et al. [16], that the presence of CHEMS in the liposome
formulation did not inhibit the effect of LLO although
cholesterol has been shown to block the LLO activity
[14]. The requirement for LLO in inducing MHC class I-
mediated antigen presentation was absolute in both APCs.
Moreover, LLO-liposome-mediated cytosolic delivery was
highly efficient at low OVA concentrations (f Ag/ml), as
compared with the fmg/ml antigen concentrations previ-
ously reported to be obligate for fluid-phase internaliza-
tion-mediated, MHC class I-restricted OVA presentation
[4,12,30]. Our in vitro data using two major APCs clearly
demonstrate LLO as a necessary and sufficient component
in pH-sensitive liposomes for efficient cytosolic delivery of
exogenous antigenic protein, further supporting our pre-
vious report on LLO-liposome-mediated cytosolic delivery
of macromolecules [16] and extending its applicability to
other cell types.
Subcutaneous immunization, which is a preferred route in
a vaccination protocol, generated overall stronger CTL
responses than i.v. immunization, although both routes of
administration engendered efficient LLO-liposome-mediated
antigen delivery. One possible explanation for the differences
observed is that the clearance kinetics and biodistribution of
PE/CHEMS liposomes depend on the sites of injection. The
induced CTLs, predominantly of CD8 + phenotype as evi-
denced by the anti-CD8 mAb blocking experiment, did not
require exogenously added IL-2 for their growth and prolif-
eration ex vivo, suggesting strong adjuvant effects of lip-
osomal immunization [15] in comparison to other previously
reported OVA model systems [4,28].
ELISPOT analysis of CTLp frequency through the quan-
tification of MHC I peptide-recognizing T cells allowed a
direct comparison of the CTL priming ability between the
immunogenic formulations. Previous studies indicated strong
correlation between the specific lysis of antigen-expressing
targets in a 51Cr release CTL assay and the frequency ofMHC
I peptide antigen-stimulated, IFN-g-secreting T cells [31].
Therefore, OVA-specific CTLp frequency was determined by
OVAMHC I peptide SIINFEKL-stimulated IFN-g ELISPOT
assay as a functional surrogate for identification of CTLp and
to test if the observed higher CTL activation by LLO-lip-
osomal OVA immunization, as monitored by the standard
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51Cr release assay, is indeed due to an increase in OVA-
specific CTLp frequency. LLO-liposome-OVA was clearly
superior to non-LLO-liposome formulation in generating
OVA-specific CTLp (Fig. 4A), which is in good agreement
with their respective CTL activities monitored (51.5% lysis
versus 22.1% lysis; P= 0.01, Fig. 3B). Therefore, the results
from ELISPOT assays evidence and confirm the enhanced
cytosolic delivery of antigen by LLO-liposome in vivo. The
observed increase in exogenous antigen-specific CTLp fre-
quency is of particular significance in a disease condition.
Cytokines produced during immune responses, including
IFN-g, play an important role in the induction of immunity,
as they are produced by complex interactions of a variety of
immuno-competent cells including T cells and APCs. IFN-g
is one of the major cytokines implicated in the priming of T
cells contributing to augmented CTL responses [32], thus
rendering antigen-specific IFN-g-producing T cells as one
of the critical effector T cell populations [33]. The ability of
splenocytes to produce OVA-specific IFN-g upon SIIN-
FEKL peptide stimulation was dramatically higher and
longer-lasting when the splenocytes were from the mice
immunized with LLO-containing formulation. This result is
in good correlation with and complementary to the superior
CTL activity induced by LLO-liposomal OVA immuniza-
tion, noting that the stimulating peptide SIINFEKL is a
MHC I-restricted (H-2Kb) epitope of OVA [4]. Antigenic
memory of the splenocytes from the LLO-liposome-immu-
nized mice was well retained over 3 months after the boost
(data not shown), demonstrating a very effective and long-
lived robust immune response, which is a hallmark of a
good vaccine formulation. Although direct evidence is
lacking, however, we cannot rule out that the prolonged
antigenic T cell memory could also be ascribed to the
immunologic activities of LLO other than its major function
of endosomolysis. It has been documented that L. mono-
cytogenes or LLO induces IL-12, which enhances CTL
activity, stimulates IFN-g production, and augments cell-
mediated immunity in mice [33,34], implying a potential
adjuvant role of LLO in the LLO-liposome immunized mice
in our system.
As our primary objective of LLO-liposome-mediated
cytosolic antigen delivery is to augment CTL responses
and maintain prolonged cell-mediated immune responses, it
is critical to assess whether the antigen-specific antibody
response, immediate and long-term, is diminished due to the
less amount of antigen being available to the MHC II
compartment. LLO-liposomal OVA immunization generated
and maintained a strong antibody response, which was
comparable to that generated and maintained by non-LLO-
liposomal OVA (Fig. 5). This indicates that LLO, at the
studied concentration inside pH-sensitive liposomes, was
unable to deliver all of the liposomal contents into the
cytosol, thereby also providing non-escaped antigens to
the MHC II pathway for priming humoral immunity. This
dual modality of the liposomal immunization was reported
for both pH-sensitive and cationic liposomes as well [8,35],
although humoral immunity in these cases was generated
more as a default pathway.
The results obtained from CTL and ELISPOT assays
evidenced superior immunogenic ability of LLO-liposome-
OVA formulation in ex vivo assays. Lethal tumor challenge
provided the opportunity to observe in vivo protection in the
immunized mice. The observed antigen-specific protection
from tumor in LLO-liposome-OVA immunized mice was
similar in nature to that of Falo et al. [25], but achieved with
less amount of antigen for immunization and with more
lethal tumor challenge. A similar level of tumor protection
was also reported by Davila and Celis [36] where mice had
to be injected repeatedly (nine times) with CpG ODN along
with OVA helper T lymphocyte epitope emulsified in
incomplete Freund’s adjuvant and challenged with 20 times
less (5 104) B16-OVA cells than our protocol. It has been
demonstrated that IFN-g, a T cell-derived cytokine, pro-
motes tumor rejection in a T cell-dependent mechanism
[37]. Mice vaccinated with LLO-liposome-OVA generated
significantly stronger CTL, higher CTLp frequency, and
OVA-specific IFN-g responses over controls and were
protected from MO5 challenge, thus, indicating a significant
role of the OVA-specific CTLs in the in vivo killing of
MO5, resulting in the delay of tumor growth and increased
survival over control group of mice.
Mice injected with LLO-liposome-OVA did not show
any apparent toxicity, monitored over 6 months post-vacci-
nation (data not shown). Thus, along with less potential
danger of pathogenic outcomes, LLO-liposome-OVAwould
be superior to other documented use of L. monocytogenes as
a delivery vehicle that has the safety concerns regarding
chromosomal integration [22]. While other existing methods
for the induction of CTL responses against exogenous
protein antigen depend on either somewhat ill-defined
‘leakage’ or nonspecific ‘disruption’ of endosomes or
plasma membranes, or ‘regurgitation’ of a fraction of endo-
somal antigenic peptide contents and thus require relatively
high concentrations of antigen [12,35], our current study
demonstrates an efficient strategy for the cytosolic delivery
of protein. This unique strategy exploits a well-defined
endosomal escape and cytosol-invading mechanism that
has been developed by the facultative intracellular bacte-
rium L. monocytogenes through evolution to achieve a
pathogenic niche in the cytosol of cells.
In conclusion, the results of the present study strongly
demonstrate the unique potential and efficacy of LLO-lip-
osome as a vaccine delivery system that is efficient in
introducing exogenous antigenic proteins into both MHC
classes I and II pathways of antigen presentation, thus
inducing both arms of immunity. This is the first in vivo
report utilizing recombinant LLO inside pH-sensitive lip-
osomes as exogenous antigen delivery system, proving its
utility and superior ability in animal models over the best
currently available liposomal formulation for cytosolic
delivery of macromolecules and demonstrating its potential
as tumor vaccine delivery vehicle. This nonviral/nonbacte-
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rial delivery vehicle is able to carry exogenous proteins, thus
making it an attractive, universal carrier for vaccine-based
immunotherapy against intracellular pathogens or cancers,
as well as for cytosolic delivery of macromolecular thera-
peutic agents.
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